Shixue Liu
Overview
Explore the profile of Shixue Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Yu H, Zhao Z
Discov Oncol
. 2025 Feb;
16(1):215.
PMID: 39976818
SOX2 is one of the members of the SOX transcription factor family, which is believed to be an important transcription factor that plays a role in embryonic development, maintenance of...
2.
Peng J, Wang D, Liu S
Medicine (Baltimore)
. 2024 Nov;
103(46):e40361.
PMID: 39560535
Background: Several studies have shown that the long noncoding RNA (lncRNA) CBR3-AS1 is overexpressed in various cancers and is playing an oncogene role. This meta-analysis aims to elucidate the relationship...
3.
Brunner H, Akikusa J, Al-Abadi E, Bohnsack J, Boteanu A, Chedeville G, et al.
Ann Rheum Dis
. 2024 Jun;
83(11):1561-1571.
PMID: 38849152
Objectives: We report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study. Methods: Patients (2-<18 years) with JIA...
4.
Cohen S, Pope J, Haraoui B, Irazoque-Palazuelos F, Korkosz M, Diehl A, et al.
Lancet Rheumatol
. 2024 Jan;
1(1):e23-e34.
PMID: 38229356
Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis. We assessed the efficacy and safety of tofacitinib after methotrexate withdrawal in patients who...
5.
Wei R, Li J, Yang W, Liu C, Wang Y, Wang L, et al.
Retina
. 2023 Nov;
44(3):527-536.
PMID: 37972986
Purpose: To investigate fundus tessellation density (TD) and its association with axial length (AL) elongation and spherical equivalent (SE) progression in children. Methods: The school-based prospective cohort study enrolled 1,997...
6.
Liu S, Jiang T, Gu J, Zhou X, Chen W, Ping B, et al.
Ophthalmol Retina
. 2023 Nov;
8(4):317-324.
PMID: 37918656
Purpose: To investigate the clinical features, risk factors, and prognosis of the intraocular recurrence in primary vitreoretinal lymphoma (PVRL). Design: Retrospective case-control study. Participants: Ninety-seven eyes of 51 patients diagnosed...
7.
Gu J, Chen Q, Zhang P, Zhang T, Zhou X, Zhang K, et al.
Ophthalmol Retina
. 2023 Oct;
8(3):264-269.
PMID: 37820767
Purpose: To explore the characteristics of vitreoretinal lymphoma (VRL) in B-scan ultrasonography. Design: Single-center case-control study. Participants: A total of 106 eyes of 56 patients with biopsy-proven VRL and 86...
8.
Chen N, He Q, Ma Y, Liu S, Wei H, Peng A
Clin Pharmacol Drug Dev
. 2023 Apr;
12(6):572-578.
PMID: 37036155
This was an open-label, randomized study in healthy Chinese participants to assess the bioequivalence of 2 fluconazole 150-mg capsules under fasted and fed conditions. The study consisted of 2 treatment...
9.
Gu J, Jiang T, Liu S, Chen X, Wang Z, Zhang P, et al.
Am J Ophthalmol
. 2023 Mar;
251:189-196.
PMID: 36963600
Purpose: To explore the trend of ocular manifestations and interleukin (IL) during the treatment of vitreoretinal lymphoma (VRL) and to evaluate the potential effects of different intravitreal administration schedules on...
10.
Leng X, Lin W, Liu S, Kanik K, Wang C, Wan W, et al.
RMD Open
. 2023 Jan;
9(1).
PMID: 36720560
Objectives: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and...